TRPV2 calcium channel promotes breast cancer progression potential by activating autophagy.

IF 5.3 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2024-09-27 DOI:10.1186/s12935-024-03506-y

Qing Li, Huixian Li, Ruiwen Zhu, William Chi Shing Cho, Xiaoqiang Yao, Fung Ping Leung, Gary Tse, Lai Kwok Leung, Wing Tak Wong

{"title":"TRPV2 calcium channel promotes breast cancer progression potential by activating autophagy.","authors":"Qing Li, Huixian Li, Ruiwen Zhu, William Chi Shing Cho, Xiaoqiang Yao, Fung Ping Leung, Gary Tse, Lai Kwok Leung, Wing Tak Wong","doi":"10.1186/s12935-024-03506-y","DOIUrl":null,"url":null,"abstract":"Breast cancer, the most prevalent and aggressive tumor affecting women, requires identification of disease determinants to facilitate the development of effective therapeutic strategies. Transient receptor potential vanilloid 2 (TRPV2), an ion channel highly permeable for calcium (Ca2+), is implicated in physiological and pathological processes. Nevertheless, the role of TRPV2 in breast cancer remains poorly elucidated. In this study, we found high levels of TRPV2 expression associated with advanced malignancy, thereby suggesting its potential as a biomarker for breast cancer staging. We demonstrated that TRPV2 activation promotes breast cancer cell proliferation, migration, and invasion, while silencing of TRPV2 suppresses breast cancer progression, highlighting the oncogenic role of TRPV2. Moreover, we reveal that TRPV2 facilitates cancer progression by modulating the CaMKKβ/AMPK/ULK1-autophagic axis through mediating calcium influx, providing new insights into TRPV2 as a novel therapeutic target for breast cancer treatment.","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"24 1","pages":"324"},"PeriodicalIF":5.3000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438410/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-024-03506-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer, the most prevalent and aggressive tumor affecting women, requires identification of disease determinants to facilitate the development of effective therapeutic strategies. Transient receptor potential vanilloid 2 (TRPV2), an ion channel highly permeable for calcium (Ca²⁺), is implicated in physiological and pathological processes. Nevertheless, the role of TRPV2 in breast cancer remains poorly elucidated. In this study, we found high levels of TRPV2 expression associated with advanced malignancy, thereby suggesting its potential as a biomarker for breast cancer staging. We demonstrated that TRPV2 activation promotes breast cancer cell proliferation, migration, and invasion, while silencing of TRPV2 suppresses breast cancer progression, highlighting the oncogenic role of TRPV2. Moreover, we reveal that TRPV2 facilitates cancer progression by modulating the CaMKKβ/AMPK/ULK1-autophagic axis through mediating calcium influx, providing new insights into TRPV2 as a novel therapeutic target for breast cancer treatment.

查看原文本刊更多论文

TRPV2钙通道通过激活自噬作用促进乳腺癌的进展潜力

乳腺癌是女性最常见的侵袭性肿瘤，需要确定疾病的决定因素，以便制定有效的治疗策略。瞬时受体电位类香草素 2（TRPV2）是一种对钙（Ca2+）具有高通透性的离子通道，与生理和病理过程有关。然而，TRPV2 在乳腺癌中的作用仍未得到充分阐明。在这项研究中，我们发现 TRPV2 的高水平表达与晚期恶性肿瘤有关，从而提示其作为乳腺癌分期生物标志物的潜力。我们证明了 TRPV2 的激活会促进乳腺癌细胞的增殖、迁移和侵袭，而沉默 TRPV2 则会抑制乳腺癌的进展，这凸显了 TRPV2 的致癌作用。此外，我们还揭示了TRPV2通过介导钙离子流入来调节CaMKKβ/AMPK/ULK1-自噬轴，从而促进癌症的进展，为TRPV2作为乳腺癌治疗的新靶点提供了新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.